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Abstract
The PI3K pathway has emerged as a key regulator of regulatory T cell (Treg) development and homeostasis and is required
for full Treg-mediated suppression. To identify new genes involved in PI3K-dependent suppression, we compared the
transcriptome of WT and p110d
D910A Tregs. Among the genes that were differentially expressed was the gene for the
transmembrane cyclic ADP ribose hydrolase CD38. Here we show that CD38 is expressed mainly by a subset of
Foxp3
+CD25
+CD4
+ T cells originating in the thymus and on Tregs in the spleen. CD38
high WT Tregs showed superior
suppressive activity to CD38
low Tregs, which failed to upregulate CD73, a surface protein which is important for suppression.
However, Tregs from heterozygous CD38
+/2 mice were unimpaired despite lower levels of CD38 expression. Therefore,
CD38 can be used as a marker for Tregs with high suppressive activity and the impaired Treg function in p110d
D910A mice
can in part be explained by the failure of CD38
high cells to develop.
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Introduction
The role of regulatory T cells (Tregs) in preventing systemic
autoimmunity and to limit inflammation is well established.
CD4
+Foxp3
+ T which develop from CD4
+CD8
+ T cell precursors
in the thymus are referred to as natural Tregs [1,2]. Induced Tregs
develop from Foxp3
2CD4
+ T cells in the peripheral immune
organs in presence of low concentrations of antigen or TGF-b
[3,4,5,6]. Tregs play a critical role in limiting the responses of not
only other T cells, but also B cells and components of the innate
immune system to antigen and/or inflammatory stimuli. Several
mechanisms have been proposed as to how Treg function [7]. The
expression of CTLA-4 is essential for Treg function by a
mechanism thought to involve the suppression of APCs [8,9].
Tregs also express high levels of CD25 which may consume
available IL-2 thus depriving T helper cells of this cytokine [10].
CD39 and CD73 expressed by Tregs generate adenosine which
has an immunosuppressive effect on Th cells [11]. Tregs also
mediate immunosuppression in different physiological contexts by
secreting the anti-inflammatory cytokines including IL-10, IL-35
and TGF-b [9,10,12,13,14,15,16].
The Class I PI3K enzymes phosphorylate the D3-position of
Phosphatidylinositol PtdIns(4,5)P2 to generate PtdIns(3,4,5)P3
which in turn is bound by proteins such as Pdk1, Akt and Itk
that contain a pleckstrin homology domain [17]. Four catalytic
isoforms of Class I PI3K are expressed in T cells: p110a, p110b,
p110c and p110d [17]. p110a, p110b and p110d form
heterodimers with SH2-domain containing p85, p55 or p50
regulatory subunits whereas p110c is bound by a p101 or p84
regulatory subunit. In T cells antigen, costimulatory and cytokine
receptors activate p110d, whereas p110c is activated by chemo-
kine receptors [18]. We have previously shown that Treg
development, differentiation and function are altered in
p110d
D910A mice which possess a kinase-dead mutant of p110d
[19]. Treg development in the thymus was enhanced whereas
there were fewer Tregs in the peripheral organs. Importantly,
p110d
D910A Tregs were impaired in their capacity to suppress the
proliferation of responder CD4
+ T cells, secreted reduced levels of
IL-10 and failed to suppress inflammation of the colon [19].
Moreover, p110d
D910A mice were resistant to infection by
Leishmania major and this was attributed to defective Treg
expansion and recruitment to the site of infection [20]. However,
despite their impaired function, p110d
D910A Tregs express similar
levels of Foxp3, CD25 and CTLA-4 [19]. Since IL-10 is not
essential for all Treg-dependent functions, this leaves open the
question of the precise nature of the suppressive mechanism that is
defective in p110d
D910A Tregs. Deletion of the p85a and p85b
PI3K regulatory isoforms in T cells resulted in a reduction in
Tregs in the spleen and development of a Sjogren’s-syndrome-like
disease; however, whether this is linked to Treg-deficiency has not
been determined [21]. More recently, Pdk1 has been shown to be
essential for Treg function, but not for Treg development, which is
consistent with this being and important signaling protein
downstream of p110d [22].
The role of PI3Ks in Treg development and function has been
further emphasized by the identification of Foxo transcription
factor binding sites in the Foxp3 promoter and by the observation
that Treg development is impaired in mice with a T cell-specific
deletion of Foxo1 and Foxo3 [23,24,25]. PI3Ks regulate Foxo
activity via Akt, which phosphorylates Foxo proteins leading to
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PI3K could lead to enhanced Foxo-dependent Foxp3 expression
and may help explain why there are more Foxp3 cells in the
thymus of p110d-deficient mice. Whether Foxo plays a similar role
in peripheral Treg is less clear given the reduced proportions of
Treg in the spleen and lymph nodes of p110d
D910A mice.
Moreover, CD4
Cre-Foxo1 mice had more Tregs in the peripheral
organs, despite reduced proportions in the thymus. The serine/
threonine kinase mTOR integrates signals for the PI3K and MAP-
kinase pathways in T cells [27]. Surprisingly, the mTOR inhibitor
rapamycin enhances differentiation of Treg cells by a mechanism
that has yet to be fully understood, but which may involve Foxp3-
dependent upregulation of Pim2 [28,29,30]. Hence, the PI3K
pathway can affect Treg numbers positively or negatively,
depending in part on their stage of development and anatomical
context.
To gain a more complete understanding of the role of p110d-
dependent transcriptional regulation in Treg development and
function we compared the transcriptome of p110d
D910A Treg with
WT Treg, and found reduced expression of the gene for the
transmembrane cyclic ADP ribose hydrolase CD38. Sorted
CD38
high Treg showed superior suppressive capacity to CD38
low
Treg. However, CD38
+/2 heterozygous Treg showed normal
suppression in vitro suggesting that reduced CD38 expression per
se is insufficient to abolish Treg activity, but rather identifies
CD38
high Tregs as a population of highly suppressive Treg that
fails to develop in p110d
D910A mice.
Methods
Mice
CD38
2/2, p110d
D910A, and RAG2
2/2 have been previously
described [31,32,33] and were maintained on the C57BL/6 (B6)
background. Congenic B6.SJL mice (in which the CD45.1 allele
from the SJL strain has been backcrossed onto the B6 genetic
background) were originally purchased from Taconic. All
experimental protocols had been approved by the UK Home
Office and local ethical review (PPL 80/1809 and 80/2248).
Reagents
The following antibodies were purchased from eBioscience or
Becton Dickinson: CD4 (GK1.5), CD8 (53-5.7), CD25 (PC61.5),
CD38 (clone 90), CD45.1 (A20), CD45.2 (clone 104), CD73-PE,
CD90.2 (53.2.1), CTLA4 (UCH10-4B9), Foxp3 (FJK-16s), GITR
(DTA-1), ICOS (15F9). Anti-CD3e (clone 145-2C11) was
prepared in-house.
Microarray experiments
RNA from 2610
6 lymph node CD4
+CD25
+ cells from 6–8
mice was isolated using Trizol, biotinylated, fragmented and
hybridised to Affymetrix GeneChip Mouse Genome 430 2.0
mouse arrays according to the manufacturer’s protocols (array
service provided by Geneservice). Three separate preparations of
RNA from each genotype were compared using GeneSpring (cut-
off: 2 fold difference, p,0.01). Microarray data has been
submitted to ArrayExpress with the accession number E-MEXP-
2955.
Quantitative real-time PCR (qRT-PCR)
cDNA was synthesized from RNA purified as above using the
Superscript II kit (Invitrogen). PCR was performed using SYBR
green PCR mastermix (Applied Biosystems) and a Chromo4
machine (Bio-Rad). Primer sequences are given in Table S1.
Bone Marrow Chimeras
RAG2
2/2 mice were irradiated with 20 gy and reconstituted
with 5610
6 cells from a 1:1 mixture of either WT:B6.SJL or
p110d
D910A:B6.SJL bone marrow. After eight weeks, the mice
were dissected and spleen cells analyzed by FACS.
Regulatory T cell purification and co-culture experiments
Tregs cells were purified using Miltenyi magnetic beads and by
FACS to greater than 98% purity. CD4
+CD25
2 cells were
purified by negative selection using magnetic beads. In some
experiments, the CD4
+CD25
2 cells were stained using 2 mM
CFSE (Molecular Probes) for seven minutes at room temperature.
For APC preparations, splenocytes were depleted of T cells by
labeling with an anti-Thy1.2 antibody (Sigma) and lysing the T
cells using Rabbit LowTox-M complement (Cedarlane, Burling-
ton, Ontario, Canada). The remaining cells were layered over
Lympholyte-M (Cedarlane) and centrifuged, with the cells from
the interface layer irradiated and used as APCs. 10
5 CD25
2
responder cells and 10
5 APCs were added to wells of a 96 U-well
plate along with 1mg/ml anti-CD3e. CD25
+ regulatory cells were
added at ratios of 1-1 to 1-32 to the CD25
2 cells. All experiments
were performed in RPMI-1640 media (Invitrogen, Paisley, UK)
containing 5% FCS (Biosera, Sussex, UK), 1% Penicillin-
Streptomycin (Sigma) and 5610
25 M 2-mercaptoethanol (Sigma).
After three days the cells were labeled with anti-CD45.1-PE, anti-
CD4-APC, anti-CD90.2-PE and anti-CD45.2 APC-eFluor780
and analyzed on a LSRII flow cytometer (BD) in a buffer
containing 2 mg/ml 7-AAD (Molecular Probes). The division
history of CD4
+CD90.2
+CD45.1
+CD45.2
27AAD
2 responder
cells was analyzed using Flowjo v8.8.6 (TreeStar, Stanford, US)
and the division index (mean divisions per divided cell) plotted.
Alternatively, proliferation was measured by
3H-thymidine
incorporation.
Differentiation of Treg from CD4+CD25
2 T cells
10
5 CD4
+CD25
2 cells were placed in culture with 10
5 APCs
and stimulated with one or more of: 1mg/ml anti-CD3e (2C11),
20 ng/ml TGF-b1 (Peprotech or eBioscience), all-trans retinoic
acid in ethanol (ATRA, Sigma) or with ethanol or DMSO at
equivalent concentrations used as a vehicle controls. 3mM PI103
(pan-class I and mTOR inhibitor, Calbiochem) and 3mM IC87114
(p110d selective inhibitor, synthesized in-house) were used to
inhibit PI3K. After three days, the cells were stained with CD73-
PE, Foxp3-Alexa647, CD38-FITC and analyzed by flow cytom-
etry.
Results
CD38 is one of a limited number of differentially
expressed transcripts in p110d
D910A Tregs
We have previously shown that p110d
D910A CD4
+CD25
+ cells
are impaired in their ability to suppress the responses of
conventional T cells [19]. To identify differentially expressed
transcripts that may lead to this impairment, cDNA from
p110d
D910A and wild type (WT) Treg cells was hybridized to
Affymetrix arrays. 125 out of 45,002 probe sets were significantly
(p,0.01 and 2-fold different) different between WT and
p110d
D910A (Fig. 1A and Table S2). Of these, 27 belonged to a
set of 603 Treg signature probe sets described by Hill et al. [34]
(Fig. 1B). However, the expression of well-characterized Treg-
associated genes, including Foxp3, CD25, CTLA-4 was unaltered,
suggesting that the CD4
+CD25
+ T cells from p110d
D910A mice
genuinely belong to the Treg lineage (Fig. 1B).
CD38 Is a Marker for Treg Suppressive Ability
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D910A
Tregs. Although most genes showed a similar pattern of
differential expression, only seven genes were confirmed to be
expressed at two-fold higher or lower levels in p110d
D910A Tregs
compared to WT Tregs by this method (Stard5, IL4, Btbd11, Plac8,
Penk1, Cd38 and Rab6b) (Fig. 1C). As CD38 has been previously
described as a marker of T cells with regulatory function [35] and
because CD38
2/2 mice bred to the NOD background are more
susceptible to develop diabetes [36], we investigated its role in
Treg biology and its regulation by PI3K.
We first defined when CD38 was expressed during T cell
development. Few CD4
2CD8
2 (double negative, DN),
CD4
+CD8
+ (double positive, DP), CD8
+CD4
2 (CD8 single
positive (CD8 SP) or CD4
+CD8
2Foxp3
2 (CD4 SP Foxp3
2) cells
from the thymus of WT or p110d
D910A mice expressed CD38
(Fig. 2A). However, high levels of CD38 were expressed on a
proportion of WT CD4 SP Foxp3
+ cells (Fig. 2A and 2B). In
contrast, significantly fewer CD4 SP Foxp3
+ cells from
p110d
D910A mice expressed high levels of CD38 (Fig. 2A and
2B). The level of CD38 expression was also higher on WT Tregs
Figure 1. Genome-wide expression-profiling of WT and p110d
D910A CD4
+CD25
+cells. CD4
+CD25
+ cells were isolated from WT and
p110d
D910A mice and RNA expression analysed by gene arrays. A. Shown is data from all 45,002 probe sets plotted as expression in WT Treg against
expression in p110d
D910A Treg (n=3 for each genotype). Black dots represent genes that were significantly differentially expressed between WT and
p110d
D910A (greater than 2-fold difference and p,0.01). B. Differentially expressed genes from A were then compared against a previously published
set of Treg signature genes [34]. The numbers of probe sets belonging in each section of the Venn diagram are shown. C. Comparison of expression
data from selected probe sets found to be significantly different in A with qRT-PCR performed on RNA from separate preparations of WT and
p110d
D910A Treg.
doi:10.1371/journal.pone.0017359.g001
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D910A CD4
+Foxp3
+ Treg cells. A. Expression of CD38 on DN, DP and CD4 and CD8 single-
positive cells from the thymus of WT and p110d
D910A mice. Mean percentages of the cells within the CD38
+ gate are for WT (bold typeface) and
p110d
D910A mice (italic). B. Summary of statistics shown in A (n=3 for each genotype). C. Expression of CD38 on Foxp3
+ and Foxp3
2 cells from the
spleen of WT and p110d
D910A mice. D. Representative FACS plots of CD38 on Foxp3
+CD4
+ T cells from the spleens of WT:B6.SJL or p110d
D910A:B6.SJL
bone marrow chimeras. E. Mean expression of CD38 on Foxp3
+ and Foxp3
2 cells from WT:B6.SJL or p110d
D910A:B6.SJL bone marrow chimeras, n=4
for WT:B6.SJL and n=3 for p110d
D910A:B6.SJL.
doi:10.1371/journal.pone.0017359.g002
CD38 Is a Marker for Treg Suppressive Ability
PLoS ONE | www.plosone.org 4 March 2011 | Volume 6 | Issue 3 | e17359than on p110d
D910A Tregs from the spleen (Fig. 2C).
Foxp3
2CD4
+ T cells of both genotypes expressed similar and
low levels of CD38, suggesting that the reduced CD38 expression
in p110d
D910A mice is limited to Tregs.
To determine if the expression of CD38 on p110d
D910A Treg is
governed by signaling within the T cells themselves or by an extrinsic
factor, competitive bone-marrow chimeras were generated. In these
experiments, we mixed WT or p110d
D910A (both CD45.2
+)b o n e
marrow cellswith bone marrow cells from B6.SJL CD45.1
+ congenic
mice and injected these mixture into lethally irradiated RAG2
2/2
mice to generate WT:B6.SJL and p110d
D910A:B6.SJL chimeras,
respectively. After eight weeks, the expression of CD38 on
CD4
+Foxp3
+ Treg from the spleens of these chimeric mice was
determined. In the spleens of WT:B6.SJL chimeras, CD4
+Foxp3
+
Treg cells from both donors showed identical expression of CD38
(Fig. 2D and 2E). However, in p110d
D910A:B6.SJL chimeras, the
CD45.2
+ cells showed a lower expression of CD38 (Figs. 2D and 2E).
The failure to express substantial amounts of CD38 is therefore due
to an intrinsic defect within the p110d
D910A Tregs.
CD38 defines a highly suppressive subset of Tregs
To determine if the level of CD38 expression corre-
lates with suppressive ability, CD4
+CD25
+CD38
high or
CD4
+CD25
+CD38
low cells were sorted from B6 mice and co-
cultured with CFSE labeled B6.SJL responder cells. After three
days CD38
high Treg cells suppressed CD45.1
+ responder cells
proliferation better than did CD38
low Treg (Fig. 3A). No
difference in the survival of CD38
low Treg at the end of the
experiment was observed (data not shown), suggesting that
equivalent numbers of Tregs were available for suppression
throughout the experiment. CD38 ligation has been described to
result in selective induction of CD73 expression [37], which in
turn is critical for Treg-mediated suppression [11]. In co-culture
experiments, CD38
high Tregs upregulated CD73 at higher Treg:T
ratios but did not affect the CD4
+CD25
2 responder cells (Fig. 3B
and 3C). We also confirmed that the level of CD73 expression was
higher on the CD38
high subset of Tregs than on the CD38
low
subset directly ex vivo (Fig. 3C). This effect appears specific to
CD73, as expression of CTLA-4 and Granzyme B was similar on
CD38
high and CD38
low cells (Fig. 3D). Hence, we have defined
two new distinct sub populations of Tregs, one that is CD38
high
and able to up-regulate CD73 and suppress the responses of other
T cells and CD38
low Treg which cannot upregulate CD73.
Reduced expression of CD38 on p110d
D910A Treg is
insufficient to cause altered Treg development
CD38
2/2 mice have reduced numbers of CD4
+CD25
+Foxp3
+
cells in the spleen, as previously reported [36] (Fig. 4B). However,
Figure 3. In vitro suppression of T cell proliferation by CD38
high and CD38
low Treg. A. Proportion of undivided CD4
+CD25
2 after three days
culture with CD38
high or CD38
low CD4
+CD25
+ Tregs. B. Expression of CD73 by CD38
high and CD38
low Tregs after suppression. C. Expression of CD73 by
CD4
+CD25
2 cells after suppression by either CD38
high or CD38
low Treg. D. Expression of CD38 versus CD73, CTLA-4 and Granzyme B on
CD4
+CD25
+Foxp3
+ cells from WT and p110d
D910A Treg cells.
doi:10.1371/journal.pone.0017359.g003
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loss of CD38 in Tregs (Fig. 2C), similar to the expression of CD38
in thymus and spleen of CD38
+/2 heterozygous mice (fig 3A). To
determine if altered number of Tregs in p110d
D910A mice is
related to their lower expression of CD38, we compared the
proportions of Tregs in the thymus and spleen of WT, CD38
+/2,
CD38
2/2 and p110d
D910A mice (Fig 4A and 4B). Unlike in
p110d
D910A mice, the proportions of Tregs in the spleen and
thymus were not altered in CD38
+/2 mice. Therefore, altered
CD38 expression on p110d
D910A Tregs is not sufficient to explain
the reductions in the numbers or function of Treg cells in
p110d
D910A mice. Moreover, CD38
+/2 Tregs suppressed the
proliferation of responder cells as well as WT Treg did, under
conditions where p110d
D910A Treg showed minimal suppression
(Fig. 4C).
CD38 is induced by ATRA on Treg cells
Expression of CD38 is regulated by several factors including the
retinoic acid receptor which binds to the CD38 promoter [38,39].
Since all-trans retinoic acid (ATRA) has been described to play a
role on Treg biology [40], we investigated its role in CD38
expression on regulatory T cells. Tregs were induced from
CD4
+CD25
2Foxp3
2 T cells by stimulating the cells with anti-
CD3 in the presence of TGF-b with or without ATRA. The pan-
PI3K inhibitor PI103, the p110d-specific inhibitor IC87114 or
DMSO vehicle control were also added to mimic the p110d
D910A
genotype pharmacologically. After three days of culture, TGF-b
induced Foxp3 which was blocked by the PI3K inhibitors. PI103
had a more potent effect suggesting that PI3K isoforms other than
p110d contribute to Treg formation in vitro. ATRA had little effect
on the proportion of Foxp3
+ cells produced either on its own or in
combination with PI103 or IC87114 (Fig. 5A). We next examined
the expression of CD38 and CD73 on TGF-b induced Treg cells.
ATRA had no effect on the proportion of Foxp3
+ Treg
developing, but enhanced the level of CD38 to the same level
found in IC87114-inhibited T cells (Fig 5B). Hence, ATRA
enhances CD38 expression on Treg. Curiously, IC87114 blocked
Treg induction, yet enhanced CD38 and CD73 expression on the
few Tregs that were induced (Fig. 5C). These results indicate that
ATRA may contribute to increased CD38 and CD73 expression
independently of p110d activity on Treg. Moreover, p110d activity
appears not to be required CD38 expression on induced Treg.
Discussion
The mechanism that underlies the impaired capacity of
p110d
D910A Treg is incompletely understood. We therefore sought
to identify other genes that may help explain the reduced function
of p110d
D910A Treg. We found 83 probe sets that showed greater
than two-fold increased expression in p110d
D910A Treg and 42
probe sets that showed reduced expression. Given the importance
of Foxo transcription factors for Treg development and the key
role p110d plays in the regulation of [30], we anticipated that Foxo
target genes would be over-represented among the genes that were
expressed at higher levels in p110d
D910A Tregs. However, there
were no candidates among the over expressed genes that are
known to us to be Foxo targets. One possibility is that such genes
might be more readily identified in arrays from acutely activated
Tregs in which Foxo may be more completely excluded from the
nucleus. Another consideration is that while PI3Ks are important
regulators of Foxo transcription factors, many downstream
signaling pathways controlled by PI3Ks regulate post-transcrip-
tional, metabolic, cytoskeletal and other relevant cellular events
[41]. Hence, inhibition of PI3K signaling can have profound
effects on cellular function without directly affecting the rates of
transcription of selected genes. It follows that some of the changes
we did note in mRNA abundance may not reflect direct
transcriptional control by Akt, Foxo and other proteins immedi-
ately linked to PI3K activity, but rather reflect broader changes in
cell biology with knock-on effects on the transcription of selected
genes.
The expression of CD38 by p110d
D910A Tregs was shown to be
reduced by the gene arrays, qRT-PCR and most importantly, at
the level of protein expression. CD38 is a transmembrane
glycoprotein which has both enzymatic activity and which acts
Figure 4. Intact development and function of Treg development in CD38
+/2 mice. Percentage of Foxp3
+ cells and mean linear fluorescence
(MLF) of anti-CD38 antibody staining on CD4
+Foxp3
+ in the thymus (A) and spleen (B) of WT, CD38
+/2, CD38
2/2 and p110d
D910A mice. (C)
Comparison of suppression of CD4
+CD25
2 proliferation by WT, p110d
D910A or CD38
+/2 Tregs.
doi:10.1371/journal.pone.0017359.g004
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to generate a wide range of products including cyclic adenosine
diphosphate ribose (cADPR), nicotinic acid-adenine dinucleotide
phosphate (NAADP) and nicotinamide [42,43,44]. cADPR can act
on ryanodine receptors on the endoplasmic reticulum to stimulate
Ca
2+ release; however its exact role is uncertain as it is generated
extracellularly and cannot readily penetrate the membrane. It has
been suggested previously that the major role of CD38 is to limit
the availability of NAD
+ to the mono-ADP-ribosyltransferase
ART2 [45]. ART2, in the presence of NAD
+, ribosylates P2X7
resulting in the rapid apoptosis of CD4
+CD25
+ cells [46,47,48].
CD38
2/2 mice show enhanced development of autoimmune
diabetes in NOD/Lt and this effect is dependent on expression of
ART2 [36]. We were unable to isolate Tregs from CD38
2/2
mice, presumably because the cells die during the preparation of
the cell suspensions [48]. However, we observed no decrease in the
survival of sorted CD38
low cells over CD38
high cells, despite the
reduced viability of CD38
2/2 Treg in vitro. Thus, minimal levels of
CD38 expression appear to be sufficient to prevent apoptosis.
CD31 (also known as PECAM) is a ligand for CD38 and in a
parallel study, we found that CD31
2/2 Treg show reduced
suppressive ability, suggesting that a potentially complex role for
CD31–CD38 interactions in Treg function [49,50]. CD38 is found
within rafts in close association with LAT and the intracellular
domain can directly bind the SH2 domain of Lck [51]. Ligation of
CD38 resultsintranslocation of severalimportant signalingproteins
to those rafts, including SOS and p85. Hence, the possibility that
CD38 transmits signals in Treg also needs to be considered.
Our results suggest that expression of CD38 on Treg cells is
controlled, probably indirectly, by p110d during the development
of Treg in the thymus. Since Treg suppression potential correlated
with CD38 expression levels in WT cells, but was unaffected on
CD38
+/2 Treg, which expressed lower levels of CD38, we
speculate that CD38 expression per se may not directly affect the
potency of Tregs, but rather correlates with a yet-unidentified
factor which promotes Treg-mediated suppression. Further
research is required to fully understand the molecular basis for
the impaired suppressive activity of p110d
D910A Tregs. Neverthe-
less, our work identifies CD38 as a marker that may be used to
purify highly suppressive Treg. This may be of use in clinical
preparation of human Tregs, for instance, where isolation of Treg
is made more challenging by the lack of cell surface proteins that
unequivocally identify Tregs. Moreover, further mining of the
dataset presented here may provide new leads in efforts to map
genes that facilitate Treg-mediated suppression.
PI3K inhibitors are currently being developed for a variety of
indications. Indeed, clinical trials have recently been initiated with
CAL-101, an inhibitor that selectively blocks p110d activation [52].
A potential consideration has been that inhibition of Treg may be
detrimental for the treatment of autoimmune diseases although
perhaps beneficial in the context of anti-cancer therapies. If the
impaired ability of p110d deficient Tregs to suppress is primarily
due to a developmental lesion (as evidenced by the CD38
low
phenotype originating in the thymus), then the current results leave
open the possibility that acute therapeutic inhibition of p110d will
not necessarily have an adverse effect on Treg function.
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Figure 5. Induction of CD38 on induced Treg cells is mildly
enhanced by IC87114 and ATRA. TGF-b-dependent conversion of
CD4
+CD25
2 cells in presence of different concentrations of ATRA and
the PI3K inhibitors IC87114 or PI103. (A) Percentage of Foxp3
+ cells after
3 days of stimulation with anti-CD3, TGF-b and indicated drugs. (B)
Mean expression of CD38 on Foxp3
+ cells induced in A. (C) Mean
expression of CD73 on Foxp3
+ cells induced in A.
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